Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

Clinical success was pre-defined as both clinical and statistical significance according to predetermined criteria, including recognition of the need for statistical multiplicity corrections as a result of the unique clinical trial design.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2009-02, Vol.123 (2), p.S57-S57
Hauptverfasser: Torkildsen, G.L, Gomes, P.J, Williams, J.I, Gow, J.A, McNamara, T.R
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Clinical trials
Drug therapy
FDA approval
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Clinical success was pre-defined as both clinical and statistical significance according to predetermined criteria, including recognition of the need for statistical multiplicity corrections as a result of the unique clinical trial design.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.12.186